Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Providence, RI, April 27, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, published new findings in the peer-reviewed journal Cancer Research that detail the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors, providing further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth.
- In two different study approaches, treatment with anti-Chi3L1 antibody in vivo resulted in over 60% reduction of human glioblastoma growth, and significant survival benefit.
- This represents a medical breakthrough in understanding how the most aggressive glioblastoma tumors are formed, and how patients diagnosed with this challenging disease might possibly be treated.
- “This is a completely new way of thinking about how to treat this tumor.
- Knowing the drivers for this heterogeneity, this is the holy grail for glioblastoma.”